BRAINnHEART: Brain Function After Cardiac Arrest (Measured With FMRI and Cognitive Tests)

Sponsor
Uppsala University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03579498
Collaborator
(none)
60
1
48.1
1.2

Study Details

Study Description

Brief Summary

The aim of this longitudinal study is to determine whether brain function is affected after a cardiac arrest.

The primary question is whether cognitive function is affected after cardiac arrest and whether it changes over time (during the first year after the event), compared with a healthy control group. Brain function during cognitive tasks and emotion processing will also be studied using functional MRI (fMRI). Another aim is to study whether clinical outcomes such as PTSD, anxiety and depression can be correlated with cognitive function and whether health- related quality of life is affected after a cardiac arrest.

The results from the cardiac arrest patient group will be compared with a healthy control group.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study is a prospective cohort study and aims to enroll 30 cardiac arrest patients and 30 matched (regarding age, gender and level of education), healthy controls.

    Patients who are enrolled in the study will on three different occasions (in the acute phase, after six and after twelve months) answer questions regarding their health state and perform a computerized cognitive test and a behavioral test.

    Patient/ control health status will be assessed through the following tests:
    • Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCa) screening tool which measures attention/concentration, executive functions, memory, verbal skills, visual construction skills, abstract thinking, computation and orientation.

    • Presence of delirium will be assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM- ICU) and will be complemented with information from the patients' medical records.

    • The Richmond Agitation - Sedation Scale (RASS) will be used to assess sedation.

    • Health- related quality of life will be measured using the three level version of EQ-5D (EQ-5D-3L; Euro-Qol 5-Dimensions).

    • A Mini International Neuropsychiatric Interview (MINI) will be performed to detect psychiatric syndromes (such as PTSD, anxiety and depression). Symptoms of anxiety and depression will also be measured using The Montgomery-Åsberg Depression Rating Scale- Self report (MADRS-S) and Impact of Event Scale-Revised -22. Alcohol use will be assessed using AUDIT (Alcohol Use Disorders Identification Test).

    Information will also be collected from the patients' medical records.

    Cognitive/ neuropsychological testing will be performed using the Cambridge Neuropsychological Test Automated Battery (CANTAB), which measures amongst others memory, planning, executive functions and attention. For this study, the following CANTAB modules will be used:

    • Delayed matching to sample (DMS)

    • Paired associate learning test (PAL)

    • Stockings of Cambridge (SOC)/ One Touch Stockings of Cambridge (OTS)

    • Motor Screening Task (MOT), which provides a general assessment of whether sensorimotor deficits or lack of comprehension will limit the collection of valid data from the participant.

    The tests are performed on a tablet. All task stimuli are non- verbal.

    An approach- avoidance test that measures avoidance behavior will also be performed. Patients will be presented with auditory and visual (pictures) stimuli and will choose whether the stimuli presented to them will be of a neutral or aversive character. Patients will be informed that choosing the aversive stimuli will reward them with a small amount of money.

    Functional magnetic resonance imaging (fMRI) will be performed six and twelve months after the cardiac arrest. The MRI scan will also include morphological images. The fMRI sequence will include tests regarding emotional activation, emotional memory and cognitive interference. A DMS task with emotionally loaded stimuli will be performed. Blood oxygenation level dependent (BOLD)- imaging will be used to produce the fMRI images, where differences in blood flow in different parts of the brain will be registered through echo planar imaging (EPI). The images will be analyzed with the Statistical Parametric Mapping (SPM)-12 program using MATLAB computing language.

    The healthy control group will on two occasions (with the second occasion taking place six months after the first) answer questions regarding their health state, perform cognitive testing and fMRI. The same will be assessed for the control as for the patient group, with the exception of CAM-ICU, RASS and information from medical records, which will not be included in the control group.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Brain Function After Cardiac Arrest (Measured With FMRI and Cognitive Tests)
    Actual Study Start Date :
    Feb 26, 2018
    Anticipated Primary Completion Date :
    Feb 26, 2022
    Anticipated Study Completion Date :
    Feb 28, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Patient group

    Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.

    Control group

    The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.

    Outcome Measures

    Primary Outcome Measures

    1. Cognitive function after cardiac arrest and changes over time [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Cognitive function in cardiac arrest survivors according to CANTAB and MoCa. Measured in the acute phase (2-6 weeks), 6 and 12 months post- cardiac arrest. Comparison with healthy controls

    Secondary Outcome Measures

    1. Health- related quality of life after cardiac arrest [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Health- related quality of life according to the three level (3L) version of Euro-Qol 5-Dimensions (5D), EQ-5D-3L, which consists of a descriptive system and a visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self- care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three levels from which the subject chooses the most appropriate statement : 1 (no problems), 2 (some problems) and 3 (extreme problems). The results are calculated as an index, ranging from -0,594 (death, or worse than death) to 1 (full health), based on normative data in the population. The EQ VAS is a scale where subjects rate their health from 0 (labeled "The worst health you can imagine) and 100 (labeled "The best health you can imagine). Measured in the acute phase (2-6 weeks), 6 and 12 months post- cardiac arrest. Comparison with healthy controls and correlation with depression, anxiety, PTSD and cognitive function.

    2. Depression after cardiac arrest according to MINI- interviews [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Prevalence of depression according to MINI- interviews. Measured in the acute phase (2-6 weeks), 6 and 12 months post- cardiac arrest. Comparison with healthy controls and correlation with cognitive function and health- related quality of life.

    3. Depression after cardiac arrest according to MADRS-S [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Prevalence of depression according to MADRS-S. The scale measures depressive symptoms and consists of nine items (mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life). Each item has seven levels (0-6, where higher scores indicate increased impairment) with described statements from which the subject chooses the most appropriate statement. The total score is then calculated as a sum of the individual scores. The total score ranges from 0 to 60 points and is interpreted as follows: 0-12 points: no depression/ essentially unaffected; 13-19 points: mild depression; 20-34 points: moderate depression; >34 points: severe depression. Measured in the acute phase (2-6 weeks), 6 and 12 months post- cardiac arrest. Comparison with healthy controls and correlation with cognitive function and health- related quality of life.

    4. Anxiety after cardiac arrest [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Prevalence of anxiety according to MINI- interviews. Measured in the acute phase (2-6 weeks), 6 and 12 months post- cardiac arrest. Comparison with healthy controls and correlation with cognitive function and health- related quality of life.

    5. PTSD after cardiac arrest [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Prevalence of post- traumatic stress syndrome (PTSD) according to MINI- interviews. Measured in the acute phase (2-6 weeks), 6 and 12 months post- cardiac arrest. Comparison with healthy controls and correlation with cognitive function and health- related quality of life.

    6. Return to daily functioning after cardiac arrest according to questionnaires and interviews [2-6 weeks, 6 and 12 months post- cardiac arrest]

      Return to daily functioning in cardiac arrest survivors. In the acute phase (2-6 weeks) patients report current and previous (prior to the cardiac arrest) occupation and living arrangements. The same questions, as well as an interview regarding self- perceived return to daily life, will be answered at 6 and 12 months after the cardiac arrest. Return to daily functioning is defined as return to the same level of independence, living arrangements, occupation, family life, social interactions as well as engagement in leisure activities as prior to the cardiac arrest.

    7. Prevalence of neuroanatomical deficits after cardiac arrest [6 months post- cardiac arrest]

      Prevalence of neuroanatomical deficits, such as infarcts, after cardiac arrest. Visualized by first MRI (6 months post- cardiac arrest). Comparison with healthy controls.

    8. Change in affective and cognitive processing, regional reactivity and connectivity measured through fMRI after cardiac arrest [6 and 12 months post- cardiac arrest]

      Change in affective and cognitive processing, regional reactivity and connectivity after cardiac arrest. Changes in regional oxygen consumption and blood flow during a DMS task with emotionally loaded stimuli will be assessed through fMRI. fMRI will be performed 6 and 12 months post- cardiac arrest. Comparison with healthy controls.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients who have suffered a cardiac arrest of cardiac cause at Uppsala University Hospital or who were admitted to this hospital after the event.

    • Age 18-70

    • Consents to participating in the study

    Exclusion Criteria:
    • Terminal disease with expected survival <1 year, moribund patient with >1 treatment limitations.

    • A history of brain injury or brain disease that affects cognitive function, such as dementia

    • Severe psychiatric disorder, for example psychotic disorders or severe alcohol use disorder

    • Insufficient knowledge of the Swedish language to understand instructions and answer questionnaires (oral or written)

    • Deceased within 1 month.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uppsala University Hospital Uppsala Sweden 75185

    Sponsors and Collaborators

    • Uppsala University

    Investigators

    • Principal Investigator: Sten Rubertsson, Prof, MD, Uppsala University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Sten Rubertsson, Professor Anaesthesiology & Intensive Care Medicine, Uppsala University
    ClinicalTrials.gov Identifier:
    NCT03579498
    Other Study ID Numbers:
    • BH001
    First Posted:
    Jul 6, 2018
    Last Update Posted:
    Oct 15, 2019
    Last Verified:
    Oct 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Sten Rubertsson, Professor Anaesthesiology & Intensive Care Medicine, Uppsala University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 15, 2019